Discogenic Pain Treatment

Coverage Summary

This policy defines UnitedHealthcare Commercial and Individual Exchange coverage rationale and evidence summary for procedures to treat discogenic low back pain: annular closure devices (ACDs), percutaneous injection of allogeneic cellular/tissue-based products into the intervertebral disc, and thermal intradiscal procedures (TIPs) (including IDET, IDB, PIRFT). The policy applies to UnitedHealthcare Commercial and Individual Exchange plans and is effective January 1, 2026.

Key facts

Effective DateJanuary 1, 2026

Policy Number2026T0105EE

Coverage StanceMixed — procedures considered unproven / not medically necessary (ACDs, allogeneic intradiscal injections, TIPs)

SubjectDiscogenic Pain Treatment (annular closure devices, allogeneic intradiscal injections, thermal intradiscal procedures)

Medical Necessity / Not Medically Necessary Criteria

Coverage Rationale - Unproven / Not Medically Necessary

The following procedures are unproven and not medically necessary due to insufficient evidence of efficacy:

ALL of the following

Annular closure devices (ACDs)
Percutaneous injection of allogeneic cellular/tissue-based products
Thermal intradiscal procedures (TIPs) for treating discogenic pain (including IDET, IDB, PIRFT)

These procedures are considered unproven / not medically necessary for treating discogenic pain because the available evidence is insufficient to demonstrate consistent benefit in patient‑oriented outcomes; see the evidence section for details on study limitations and mixed results.

Procedure and Product Codes

Referenced Procedure Codesmixed

0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level.
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure).
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level.
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure).
22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level.
22527	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure).
22899	Unlisted procedure, spine.
63032	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; with repair of annular defect by implantation of bone-anchored annular closure device, including all imaging guidance, 1 interspace, lumbar (List separately in addition to code for primary procedure).
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar.

Applicable CPT codes (updated)CPT

63032

Laminectomy, facetectomy and foraminotomy (unilateral or bilateral) with decompression of spinal cord, cauda equina and/or nerve root(s), single vertebral segment; lumbar

FDA product codes (informational)mixed

FTL	Surgical mesh, polymeric
FTM	Mesh, surgical
GAT	Suture, nonabsorbable, synthetic, polyethylene
GEI	Electrosurgical cutting and coagulation devices and accessories (product code)
GXI	Electrosurgical cutting and coagulation devices and accessories (product code)
HRX	Electrosurgical cutting and coagulation devices and accessories (product code)
BSO	Electrosurgical cutting and coagulation devices and accessories (product code)
BSP	Electrosurgical cutting and coagulation devices and accessories (product code)

Billing Rule

CPT code list updated

Applicable CPT code 63032 was added to the policy's CPT code list as part of the 01/01/2026 revision.

63032
Revision note: Updated list of applicable CPT codes to reflect annual edits; added 63032 (01/01/2026).

Provider Actions & Operational Notes

Documentation Required

Reference other policy for percutaneous discectomy

For percutaneous discectomy for treatment of axial or radicular pain, refer to the Medical Policy titled Minimally Invasive Spine Surgery Procedures.

Documentation Required

Reference member-specific benefit plan

When deciding coverage, reference the member-specific benefit plan document as it governs in the event of a conflict with this policy; check applicable federal/state mandates before use.

Background & Evidence Summary

Background: Annular closure devices (ACDs) are implantable, often bone‑anchored devices intended to reinforce or close annular defects after discectomy to reduce recurrent herniation. Percutaneous allogeneic cellular/tissue injections deliver donor-derived biologic material into the nucleus/annulus to stimulate repair. Thermal intradiscal procedures (TIPs) — including intradiscal electrothermal therapy (IDET), intradiscal biacuplasty (IDB), and percutaneous intradiscal radiofrequency thermocoagulation (PIRFT) — apply heat via probes or radiofrequency to modify disc tissue and nociceptors. The policy reviews systematic reviews, randomized controlled trials, technology assessments (Hayes, ECRI), cohort studies, and case series to evaluate safety and efficacy.

Study / Source	Key Finding
Dalal et al. (2025)	Meta-analysis: Barricaid associated with 53% lower symptomatic reherniation risk but no significant differences in reoperation rates or PROMs; higher complications in ACD group; heterogeneous small studies—mixed quality (amber)
Wang et al. (2024)	Meta-analysis of 15 studies: annular repair reduced postop recurrence and reoperation; Barricaid more effective than suture; some serious adverse events reported—favorable for recurrence but safety/ bias concerns (amber)
Hayes assessment (2024/25)	Tech assessment: overall low quality evidence for ACDs; 2025 update found no new qualifying studies—confidence limited (amber)
ECRI (2020, updated 2023/2025)	Clinical evidence assessment: evidence somewhat favorable for Barricaid but at risk of bias; additional RCTs needed—cautious/uncertain (amber)
VAST RCT / Beall et al.	Randomized trial of viable disc allograft (ViaDisc NP): mixed results with no clear benefit over placebo on main outcomes at <12 months; single RCT insufficient—insufficient evidence (amber)
Helm systematic review (2017)	Systematic review found Level I evidence for biacuplasty and Level III for IDET based on few RCTs; overall limited trial numbers and small samples (amber)
Kvarstein RCT (2009)	Double-blind RCT of PIRFT (discTRODE): no benefit vs sham at 6 months and no significant difference at 12 months; study stopped early for futility—negative/low benefit signal (not_covered)
Small case series / pilot studies	Uncontrolled small studies (bipolar RFTC, L'DISQ, single-arm allograft feasibility) report pain/function improvements but limited by lack of control and small size—suggestive but low-quality (amber)
ISASS (2025)	Review: nine studies (1,311 pts) and multiple meta-analyses conclude bone-anchored annular closure reduces recurrent LDH and reoperation in patients with large (≥6 mm) annular defects—supports benefit in selected high-risk patients (neutral)
NICE (2016)	IPG: percutaneous electrothermal and PIRFT raise no major safety concerns but efficacy evidence is inconsistent and limited; recommends further research (amber)
NASS (2020)	Guideline: insufficient evidence to recommend for or against PIRFT—no clear support (amber)
FDA Barricaid PMA (2019)	PMA approval: indicated to reduce reherniation and reoperation in skeletally mature patients with large annular defects (4–6 mm tall, 6–10 mm wide) after single-level L4–S1 discectomy; regulatory approval exists but evidence debates remain (neutral)

Definitions

Annular Closure Device (ACD)Implantable device intended to reinforce or close annular defects after discectomy to prevent recurrent herniation.

Thermal Intradiscal Procedures (TIPs)Percutaneous procedures applying heat within the disc (IDET, IDB, PIRFT) to modify tissue and nociceptors for pain relief.

Percutaneous injection of allogeneic cellular/tissue-based productsInjection of allogeneic biologic cell or tissue products into the intervertebral disc aiming to stimulate repair.

Not Medically Necessary / Experimental Procedures

Unproven / Not Medically Necessary (Not Medically Necessary / Experimental)

The following procedures are unproven and not medically necessary due to insufficient evidence of efficacy:

ALL of the following

Annular closure devices (ACDs)
Percutaneous injection of allogeneic cellular/tissue-based products
Thermal intradiscal procedures (TIPs) for treating discogenic pain (including IDET, IDB, PIRFT)

Rationale: Across these technologies the quantity and quality of evidence are limited and outcomes are mixed — randomized trials are few or small, many studies are nonrandomized or industry‑sponsored, and longer‑term or generalizable data are lacking. An important regulatory nuance is that the Barricaid bone‑anchored annular closure device received FDA premarket approval (PMA K201676) with a labeled indication for select patients with large annular defects, which differs from the overall evidence base for annular repair devices.

Definitions

Definitions: The following definitions are provided to clarify terms used in this policy and to guide clinical interpretation of the coverage criteria and evidence for healthcare professionals.

Key Terms

Revision History

01/01/2026revisionLatest

Template Update creating shared policy version to support application to Oxford plan membership and updated applicable CPT codes (added 63032). Clinical Evidence and References sections were updated; previous policy versions archived (2025T0105DD and OUTPATIENT 037.25).